A prostate-cancer treatment moves earlier, guided by the tumor’s genes

Cancer and precision medicine · Source date: October 26, 2026 · Evidence: U.S. regulatory decision supported by randomized, double-blind phase 3 trial · Primary source

A genetic test can now change the treatment discussion earlier in metastatic prostate cancer. On October 26, the FDA expanded the approved use of talazoparib with enzalutamide to adults whose metastatic tumors carry specified homologous-recombination-repair (HRR) gene mutations and whose disease is still sensitive to, or has not received, androgen-pathway modulation. Eligibility depends on an FDA-authorized tissue or circulating-tumor-DNA test. That is a consequential clinical application of genomics: a result changes which treatment is indicated, not simply how risk is described.

The TALAPRO-3 study randomized 599 patients to talazoparib or placebo added to enzalutamide and androgen-deprivation therapy. Radiographic progression or death was less frequent with the combination (hazard ratio 0.48; 95% CI 0.36–0.65). Median radiographic progression-free survival had not been reached in the talazoparib arm, versus 45.8 months in the comparison arm. Overall-survival data were immature. The FDA label also warns about myelosuppression, myelodysplastic syndrome/acute leukemia, and embryo-fetal toxicity.

Timely molecular testing matters because an eligible result changes treatment options. Its benefit here was measured on imaging; a survival gain has not yet been established.

verify exact label, assay, comedications and coverage before workflow adaptation.